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Abstract
Background—Kidney transplant recipients (KTRs) have increased risk for cardiovascular 
disease (CVD). Our objective is to describe the prevalence of CVD risk factors applying standard 
criteria and use of CVD risk factor lowering medications in contemporary KTRs.
Methods—The Folic Acid for Vascular Outcome Reduction in Transplantation study enrolled 
and collected medication data on 4,107 KTRs with elevated homocysteine and stable graft 
function an average of 5 years post-transplant.
Results—CVD risk factors were common (hypertension or use of blood pressure lowering 
medication in 92%, borderline or elevated LDL or use of lipid-lowering agent in 66%, history of 
diabetes mellitus in 41%, and obesity in 38%); prevalent CVD was reported in 20% of study 
participants. National Kidney Foundation blood pressure (BP) guidelines (BP < 130/80 mm Hg) 
were not met by 69% of participants. Uncontrolled hypertension (BP of 140/90 mm Hg or higher) 
was present in 44% of those taking anti-hypertension medication; 18% of participants had 
borderline or elevated LDL, of which 60% were untreated, and 31% of the participants with 
prevalent CVD were not using an anti-platelet agent.
Conclusion—There is opportunity to improve treatment and control of traditional CVD risk 
factors in kidney transplant recipients.
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Introduction
Cardiovascular disease (CVD) is much more common among kidney transplant recipients 
than the general population (1–3). This burden is not entirely explained by traditional risk 
factors such as hypertension, dyslipidemia, and diabetes (4). Other factors may be involved, 
particularly those which may influence systemic inflammation including graft rejection, 
infection, and use of immunosuppressive medications (1–3).
Kidney transplantation reduces CVD risks in patients with end-stage renal disease (5). 
Compared to patients on a transplant wait list, kidney transplant recipients experience a 
marked reduction in the CVD death rate, especially from adolescence onward (6). Despite 
this benefit, kidney transplant recipients, particularly those age 25 to 55 years, have 
substantially more CVD mortality than their age, gender, and race matched non-dialysis 
counterparts. Some of the increased risk for CVD in the kidney transplant population could 
be related to lower levels of kidney function, as compared to the general population (7–9). In 
the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) study, we 
demonstrated increased risk in both CVD and all-cause mortality, with the association 
between estimated glomerular filtration rate (eGFR) and CVD being comparable in 
magnitude to that of systolic blood pressure and age (10). Consequently, efforts should be 
focused to control traditional cardiovascular risk factors in kidney transplant recipients 
including blood pressure, cholesterol, and glucose, and to counsel patients to increase their 
physical activity, stop smoking, and achieve or maintain acceptable body weight (11).
We describe the use of CVD risk-reducing medications in kidney transplant recipients 
overall, by country, and in subgroups defined by graft vintage and presence of risk factors 
including diabetes. As a multi-national study, FAVORIT provides a unique opportunity to 
consider the similarities and meaningful differences in participant characteristics including 
CVD risk factors and use of risk factor lowering medications. Participant grouping by graft 
vintage is useful in considering medications that include agents or classes with varied 
availability and use over the past two decades.
Materials and Methods
Details regarding the design of the clinical trial and general baseline data have been 
published elsewhere (12, 13). Briefly, the FAVORIT study was a randomized, double-blind 
controlled clinical trial to evaluate the impact of homocysteine-lowering vitamin therapy on 
cardiovascular disease in stable kidney transplant recipients. Study participants were 
enrolled from August 2002 through January 2007 at 27 clinical sites in the United States, 
two sites in Canada and one site in Brazil. We report data from the baseline visit. The study 
was approved by the applicable ethics board or institutional review board at each 
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participating site, and each study participant provided written informed consent prior to 
enrollment.
Male and female kidney transplant recipients who were 35 to 75 years of age with elevated 
total homocysteine levels (≥ 11 μmol/L for women; ≥ 12 μmol/L for men) and stable graft 
function were eligible. All participants were required to be at least 6 months post-transplant 
and have a Cockcroft-Gault (14) estimated creatinine clearance (Ccr) of 30 mL/min or 
greater (25 mL/min or greater for women recruited after July 2005 to reflect the generally 
lower Ccr distribution in females). Patients with recent CVD events or CVD-related 
procedures that would temporarily increase the risk of a cardiovascular event and those with 
chronic illness limiting life expectancy to less than two years were ineligible.
During the baseline visit, data collection included information on health history and 
medication use, a brief physical examination, and a lipid profile. Kidney graft vintage was 
defined as the time (years) between the most recent transplant prior to enrollment and date 
of randomization. Graft vintage tertiles were rounded to nearest whole year to identify cut 
points for categorization. Cardiovascular disease history was assessed from medical record 
review and participant report. Height and weight were obtained with shoes removed, but 
while wearing street clothes. Two blood pressure measurements were taken approximately 
5–10 minutes apart, with the average being used for analysis. Blood pressure (BP) was 
classified as elevated if it was 130/80 mm Hg or greater. (15) Participants were considered 
to have prevalent hypertension if regular use of a prescription blood pressure lowering 
medication was reported or if systolic BP was 140 mm Hg or greater, or diastolic BP was 90 
mm Hg or greater. Participants who were taking an anti-hypertensive medication and had a 
baseline systolic BP of 140 mm Hg or greater or a diastolic BP of 90 mm Hg or greater were 
considered to have uncontrolled hypertension. Obesity was defined by a body mass index of 
30 or higher.
Prescription medications taken regularly during the past month were recorded by study staff 
during participant interview. Risk factor lowering medications categorized and recorded 
were as follows:
• blood pressure lowering medications: angiotensin converting enzyme inhibitors 
(ACEi), angiotensin receptor blockers (ARB), beta blockers, dihydropyridine 
calcium channel blockers, non-dihydropyridine calcium channel blockers, loop 
diuretics and other diuretics
• lipid lowering medications: HMG COA reductase inhibitors, bile acid 
sequestrants, niacin, gemfibrozil, fenofibrate, bezafibrate, clofibrate, probucol and 
ezetimibe
• anti-platelet medications: aspirin, clopidogrel, ticlopidine and other anti-platelet 
agents
• anti-diabetic agents: insulin, sulfonylureas, rosigliatazone, pioglitazone, 
metformin, and other anti-diabetic agents
Serum creatinine, homocysteine and lipid panel were analyzed at a central laboratory (Jean 
Mayer USDA Human Nutrition Research Center on Aging, Boston, Massachusetts). 
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Homocysteine data in this report are from the screening visit which occurred up to 120 days 
prior to randomization. Homocysteine was measured by high-performance liquid 
chromatography with fluorescence detection. Baseline creatinine was measured by a 
modified Jaffe method using an Olympus U400 analyzer that met isotope-dilution mass 
spectrometry standards. The Chronic Kidney Disease Epidemiology Collaboration equation 
(16, 17) was used to calculate eGFR that, in turn, was used to classify participants by stage 
of kidney disease (18). Cholesterol, high density lipoprotein (HDL) and triglyceride levels 
were assessed by direct measurement using an Olympus U400 analyzer. Low density 
lipoprotein (LDL) was measured directly if triglyceride was 400 mg/dL or higher; otherwise 
it was calculated. (19) LDL levels of 130 mg/dL (3.4 mmol/L) were considered elevated. 
(20, 21)
All statistical analyses were computed using SAS, version 9.2 (SAS Institute, Cary, NC). P-
values for country and disease history comparisons of categorical variable were based on 
chi-square test for homogeneity unless any cell counts were less than 10 in which case 
Fisher’s Exact Test was used. Analysis of variance (ANOVA) F test was used for evaluating 
continuous variables, with transformations to normalize variables with severely skewed 
distributions. Age did not require transformation; homocysteine was transformed using the 
negative reciprocal; other continuous variables were log transformed.
Results
Study Subjects
A total of 7,273 patients were screened, of which 4,753 met eligibility criteria for Ccr and 
elevated homocysteine level. Of these, 4,110 participants met additional eligibility criteria 
and were enrolled. Three subjects with missing medication data were excluded. Baseline 
participant characteristics are summarized in Table 1. We report on 1,527 women and 2,580 
men with a mean age of 52 years (SD=9.4) who were enrolled on average 5 years after 
kidney transplantation. Statistically significant differences in participant characteristics by 
country are evident, though the magnitude may not be clinically relevant. Baseline 
characteristics were also examined by categorized graft vintage (data not shown). Subjects 
did not differ in age, sex, smoking history, prevalence of hypertension, history of diabetes 
mellitus, CVD history, and BMI across graft vintage categories. However, there were fewer 
participants of non-white race among those transplanted more than 6 years (19%) than 
among those with more recent transplants (29%) and those with graft vintage of 2–6 years 
(26%, p<0.001). Older graft vintage was also associated with lower mean eGFR (46 ml/min 
per 1.73 m2; p<0.001) and lower mean triglyceride levels (188 mg/dL; p<0.002) than the 
intermediate (50 ml/min per 1.73 m2; 197 mg/dL) and younger (51 ml/min per 1.73 m2; 214 
mg/dL) graft vintage categories.
CVD, Risk Factors and Medication Use
At study entry, 820 participants (20%) reported a history of CVD, including 566 participants 
(14%) with previous myocardial infarction or coronary heart disease. Ninety-two percent of 
those enrolled had prevalent hypertension; 69% had blood pressure of 130/80 mm Hg or 
higher. Uncontrolled hypertension, history of diabetes mellitus, and obesity were common 
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risk factors present in 44%, 41% and 38%, respectively in this cohort; elevated LDL (130 
mg/dL or higher) was present in 18% of participants.
Table 2 summarizes medication use at baseline. Overall, 89% of participants were taking a 
blood pressure (BP) - lowering medication, 55% a lipid-lowering agent, and 29% an anti-
diabetic medication. Of 1,662 participants with a history of diabetes, 72% were prescribed 
an anti-diabetic agent. Specific medication use frequently differed by graft vintage. The 
association between graft vintage and use of CVD risk factor lowering medications was 
inconsistent and unrelated to overall use of BP-lowering medications, whereas lipid-
lowering agent use was less prevalent and anti-platelet use, primarily aspirin use, was more 
prevalent among those with grafts in place less than 2 years than in participants with older 
vintage grafts. For example, among participants with a graft vintage of two or more years, at 
least 58% took a lipid lowering medication in comparison to 48% of those with grafts in 
place less than two years. Conversely, anti-platelet use was more prevalent among those 
more recently transplanted (47%) than among participants with older vintage grafts (40%–
42%). Anti-diabetic agent use was most prevalent among those receiving grafts within the 
past 2 years (33%) versus those with grafts more than 6 years (26%), perhaps reflecting 
survivor bias. Among immunosuppression medications, while prednisone use was 
consistently high across all graft vintage categories (90–92%), cyclosporine A use was more 
prevalent in participants transplanted at least 6 years (68%) whereas use of mycophenolate 
mofetil (77%) and tacrolimus (59%) were more frequent among those with more recent 
transplants.
Medical management of risk factors—Medical management of CVD risk factors is 
summarized in Table 3. Of 2,817 participants with elevated blood pressure (130/80 mm Hg 
or higher), 90% were using at least one blood pressure lowering medication, and 61% were 
taking two or more medications. Of those using one or more anti-hypertensive medications, 
70% had blood pressure of 130/80 mm Hg or higher and 44% had blood pressure of 140/90 
mm Hg or greater. Elevated low density lipoprotein (LDL ≥ 160 mg/dL) was identified in 
209 participants, of which only 85 (41%) reported regular use of a lipid-lowering agent. Of 
the 2,164 participants who were taking a lipid-lowering agent and had baseline cholesterol 
data, 87% had a baseline LDL less than 130 mg/dL and only 4% had LDL levels of 160 
mg/dL or greater. Only 159 participants reported regular use of more than one lipid lowering 
medication; of these, 143 (90%) had baseline LDL less than 130 mg/dL.
CVD risk factor lowering medication use was more prevalent among participants with a 
prior history of CVD events or procedures (Table 4). This association was most evident for 
use of anti-platelet agents with 69% of subjects with a history of CVD using an anti-platelet 
agent in comparison to only 36% of those without a CVD history. Also among those with a 
CVD history, 66% were taking a lipid-lowering medication and 93% were using an anti-
hypertensive medication versus 53% and 87%, respectively, of those participants without a 
history of CV events or procedures. Use of CVD risk factor lowering medications was 
greater among participants with a history of diabetes in comparison to those without 
diabetes. Participants with a history of both diabetes and CVD (n=496) were most likely to 
be using blood pressure lowering medication, lipid-lowering medication, or anti-platelet 
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agents, whereas those with neither risk factor (n=2,110) were least likely to use these 
medications.
Discussion
The FAVORIT study reveals that traditional CVD risk factors continue to be over-
represented in the kidney transplant population. Although the burden of CVD (20%), 
diabetes mellitus (41%), borderline or elevated LDL or use of lipid-lowering medication 
(66%), and obesity (38%) is substantial approximately 9 out of 10 participants had 
hypertension defined as blood pressure >140/80 mmHg. Of greatest concern is the level of 
uncontrolled elevated blood pressure that remains after medical management is attempted: 
70% of participants taking at least one blood pressure lowering medication had a blood 
pressure level that failed to meet the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative (NKOQI) (15) recommended target of less than 130/80 mm Hg.
The use of cardiovascular risk reducing medications in renal transplant recipients remains a 
challenging problem. This is in large part due to the numerous medications prescribed, 
concerns about patient adherence, medication tolerability and drug: drug interactions that are 
integral to management of the renal transplant recipient. Patients are often taking two or 
three immunosuppression medications, two or three anti-infective agents, a proton pump 
inhibitor or an H2 blocker, as well as other medications for medical co-morbidity 
management. Common comorbidities include hypertension, diabetes, and dyslipidemia. 
Thus, patients may often be taking 6–10 medications directly related to transplantation 
before a clinician considers the addition of cardiovascular risk-reducing therapies. 
Moreover, drugs such as HMG-CoA reductase inhibitors (statins) may interact with 
cyclosporine (22), and cause myopathy or liver enzyme elevations, and bile acid 
sequestrants may interfere with drug absorption (23). These concerns may limit 
implementation of these drugs. Additionally, drugs such as renin angiotensin system 
blockers, which have proven beneficial in the general population for treating heart (24–26) 
and kidney disease progression (27, 28), may be associated with acute changes in serum 
creatinine or potassium, and cause a mild reduction in serum hemoglobin (29). As a 
consequence, clinicians may be willing to tolerate higher levels of blood pressure, and 
greater degree of lipid abnormalities given concerns about drug: drug interactions, patient 
tolerability and the concern that prescribing more medications may lead to medication non-
adherence.
Cardiovascular disease is the leading cause of death with a functioning graft in the renal 
transplant population (30). Transplant recipients often present for transplantation with 
increased CV risk (31), and the majority of patients have hypertension and/or diabetes. 
Despite the improved life expectancy post-transplantation (30) the underlying CV risks can 
be compounded by post-transplant risk factors; inadequately controlled hypertension, 
suboptimal diabetes control, hyperlipidemia, chronic kidney disease and ongoing tobacco 
use (32). In addition, hyperhomocysteinemia has been a postulated risk factor for 
atherosclerosis and was the impetus for the implementation of this study (33, 34). Chronic 
kidney disease in itself has been postulated to contribute to cardiovascular risk (4, 7, 8).
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Cardiovascular disease influences the candidacy for transplant. This may explain part of the 
variation by country in history of CVD that we report. Also, the observed differences by 
country in the history of diabetes may reflect some variation in definitions, comorbidities, 
and associated eligibility for transplant between centers.
Our study captures a different population than the recent study (11) that retrospectively 
evaluated cardiovascular medication use in 14,236 transplant patients from the PORT 
(Patient Outcomes in Renal Transplantation) study. Pilmore and colleagues report a study 
that included a lower proportion of patients with cardiovascular disease (4.7% previous MI, 
6.8% a revascularization procedure, and 3.7% history of stroke) and smaller percentage of 
diabetes at the time of transplant (27.9%) than was observed in our chronic stable renal 
transplant cohort. Therefore, participants in our prospective FAVORIT study were 
inherently at higher risk for cardiovascular events than the patients in the retrospective 
PORT study.
Anti-platelet therapy is a mainstay of cardiovascular disease prevention and is standard of 
care in patients with known CVD. The overall use of acetylsalicylic acid (ASA) was 
suboptimal for a population with high CVD risk, but varied by graft vintage. The greater use 
of ASA among recent recipients (45%) in comparison to those greater than six years from 
transplant (38%) may reflect either greater confidence in using ASA early post 
transplantation, transplanting a higher risk population, or possibly ASA being stopped for 
intolerance or other reasons and not being restarted in patients who were further out from 
transplant. Another consideration is that the ASA use may be an extension of its use to 
maintain graft patency, unrelated to use as a cardiovascular risk lowering agent. Our study 
demonstrates that those patients at greatest risk for a cardiovascular event, those with 
diabetes with known CVD, are most likely to be using antiplatelet therapy (73%) in contrast 
to the lowest risk patients, the non-diabetic, with no history of CVD (29%).
Hypertension is a leading cause of chronic kidney disease and a risk factor for 
cardiovascular disease. Blood pressure control in kidney transplant recipients is particularly 
challenging. The KDOQI (15) recommendations included that most transplant recipients be 
treated with a regimen drawn from calcium channel blockers, diuretics, ACEi, ARBs, and 
beta blockers to reach a target blood pressure less than 130/80 mm Hg. Patients less than 
two years from transplant were more likely to be on a beta-blocker and less likely to be on a 
diuretic than participants greater than six years out from transplant. The more frequent use 
of beta blockers in the population of subjects within two years of transplant may reflect a 
practice of using perioperative beta blockers for cardioprotection. The use of angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers may have been limited in the 
past out of concern for elevating the serum creatinine and causing hyperkalemia. This is 
most problematic in the first 6–12 weeks post-transplant. Use of ACEi and ARBs are felt to 
offer both renal and cardio-protective benefits once renal function has stabilized. Our cohort 
includes only patients with stable renal function, greater than six months from transplant and 
therefore reflects the greater comfort level in using these agents. Nevertheless, the use of 
this class of agent was relatively low in our cohort despite the purported benefit of ACEi and 
ARB in stabilizing renal function.
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The focus of this paper is to evaluate the use of cardiovascular disease risk-lowering 
medications in stable renal transplant recipients. Of greatest interest is the frequency of use 
of these medications in patients with a known history of cardiovascular disease and those at 
greatest risk for cardiovascular events, specifically diabetic patients. Beta-blocker use for 
those with known cardiovascular disease imparts improved survival. While our study 
identified a sizable proportion of participants with a history of CVD who were not taking a 
beta blocker, we did not ascertain the reasons why such medications were not prescribed or 
being used by participants.
The strength of this study is in the design, size, and diversity. It aimed to capture a specific 
population of renal transplant recipients with elevated homocysteine and to evaluate 
cardiovascular events in a rigorous and standardized fashion. The FAVORIT trial is the 
largest known trial designed specifically to evaluate cardiovascular outcomes in renal 
transplant recipients. The mixture of clinical sites and large number of participants provides 
an excellent cohort for examining contemporary characteristics of renal transplant recipients 
and associations of the characteristics with cardiovascular and renal outcomes.
The main issue is what is the impediment to maximizing appropriate care of the renal 
transplant patient? There are likely several contributing factors, not the least of which is who 
is taking primary responsibility of the patient’s medical care? Primary care physicians are 
often reluctant to adjust medication out of concern for disturbing the delicate balance of 
medications inherent to a transplant recipient. Transplant physicians are often focused on the 
primary issues related to managing renal function. There is also concern about 
polypharmacy with the number of medications a patient must take and the associated drug 
interactions. Improvement in care of renal transplant patients should not be overlooked as 
health care systems and guidelines are updated. For example, electronic medical record 
systems might be customized to prompt transplant physicians to consider CV risk reduction 
strategies at specific milestones post-transplant. As concerns about the early risks of 
infection and rejection are lessened, increasing attention can focus on prevention of CVD 
and other longer term complications. A collaborative management approach is essential to 
optimize medical management of the kidney transplant recipient.
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